Xenetic Biosciences (NASDAQ:XBIO) and Novavax (NASDAQ:NVAX) Critical Survey

Novavax (NASDAQ:NVAX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Valuation and Earnings

This table compares Novavax and Xenetic Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12 billion	1.28	$440.30 million	($0.46)	-18.90
Xenetic Biosciences	$2.98 million	1.33	-$2.68 million	($1.16)	-1.49

Novavax has higher revenue and earnings than Xenetic Biosciences. Novavax is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Novavax has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500.

Profitability

This table compares Novavax and Xenetic Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novavax	-18.64%	-14.82%	-7.55%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Novavax and Xenetic Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3	2	5	0	2.20
Xenetic Biosciences	1	0	0	0	1.00

Novavax currently has a consensus price target of $12.33, suggesting a potential upside of 41.84%. Given Novavax’s stronger consensus rating and higher probable upside, equities analysts plainly believe Novavax is more favorable than Xenetic Biosciences.

Insider & Institutional Ownership

53.0% of Novavax shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Novavax beats Xenetic Biosciences on 11 of the 14 factors compared between the two stocks.

About Novavax

Novavax, Inc. is a biotechnology company focused on developing vaccines for infectious diseases. Its technology combines recombinant protein-based vaccine antigens with Matrix-M, a saponin-based adjuvant designed to strengthen the immune response. The company’s best-known product is Nuvaxovid, a protein-based COVID-19 vaccine authorized in the United States and other markets. Novavax also develops additional vaccine candidates, including a combination COVID-19 and influenza vaccine. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax serves international markets through regulatory approvals and commercial partnerships.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for oncology indications. The company’s primary focus is its XCART platform, an autologous cell-therapy technology designed to modify a patient’s own T cells to recognize and attack cancer cells. Xenetic has applied the XCART platform to potential treatments for B-cell malignancies, including programs intended to target specific antigens found on cancerous B cells. The company’s research and development activities have centered on advancing personalized immunotherapies through preclinical and clinical development.